Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception
about
sameAs
Progesterone receptors: form and function in brainOral contraceptives and breast cancer risk overall and by molecular subtype among young women.Oral contraceptives cause evolutionarily novel increases in hormone exposure: A risk factor for breast cancer.Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age.Nomegestrol acetate-17b-estradiol for oral contraception.Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations.New progestagens for contraceptive use.An update on new orally administered contraceptives for women.The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor.Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.Designer androgens in sport: when too much is never enough.Fourth-Generation Progestins Inhibit 3β-Hydroxysteroid Dehydrogenase Type 2 and Modulate the Biosynthesis of Endogenous Steroids.Pharmacology of different progestogens: the special case of drospirenone.An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk.Progestin therapy of complex endometrial hyperplasia with and without atypia.Effect of carbamates on mRNA encoding lipid enzymes in hamster flank organs.The effects of progesterones on blood lipids in hormone replacement therapy.A Scalable and Versatile Synthesis of Oxime-Based Hormone Dimers and Gels for Sustained Release.Contraception for women with epilepsy: counseling, choices, and concerns.Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.Effects of estradiol-drospirenone hormone treatment on carotid artery intima-media thickness and vertigo/dizziness in postmenopausal women.Proliferation of Breast Cells by Steroid Hormones and Their MetabolitesHearing Performance in the Follicular-Luteal Phase of the Menstrual Cycle
P2860
Q28274391-13484A71-C18A-4B49-A8B7-3CC1E287AE04Q33655313-582B7A62-4835-42D3-A218-5E5C503747BEQ33862767-3B4EC762-FB9A-4218-A628-A15C979B0912Q34132946-EF0D60E8-37CB-4A19-A19B-00BA105754F3Q34356201-67F00730-7403-4C09-AD57-78F807DE9E9DQ34372874-575E593B-EB91-466D-8483-28599CC31E00Q34448921-3A03B7ED-3DDF-47AC-92F0-61F4CB73C3B2Q34468158-4D6EA38C-5E2E-46CD-B959-1060AC696C5DQ34499804-43C38192-2289-49F1-822D-FBC8B9277CEAQ34712821-B0E02B5F-D631-4626-BA97-6DE7114145DFQ34851491-1295015D-7DDE-4EA0-9FE6-74768089BA1AQ35855152-19FCFF1B-812E-4512-8960-69976339B9D0Q36153866-CDC3DF50-3AA0-4198-A19C-8D880C9E6388Q36276322-3DF11581-DA68-418E-B3C5-E3E7DF91EA0CQ36615906-0E20396E-90A2-4A4A-8B78-D5C18997A42FQ37187921-94FBC116-0FD6-41CF-BD95-55F9C31F49C8Q44504918-77559D3C-E763-44B5-A003-8F59D518AF03Q47102333-4EA37A24-AA46-4978-A886-9E9CB2143531Q48267030-6E5094A0-CD6A-4A2A-8BC1-17123F0AE46EQ49540132-C4058276-97DF-4D49-ADDF-6C3866E05C1CQ51129728-F7919382-2ADE-4D89-99C9-F38D17B369E9Q51401165-4A03C1DE-A9CB-47D6-8E61-ECEE250A2B3DQ57382352-8DFEB2B1-4148-4DEC-9169-99EA54EC9C7DQ58766174-902F73EB-DEBA-4E1C-B295-7523B6D18B32
P2860
Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Pharmacokinetics and potency o ...... ment therapy and contraception
@ast
Pharmacokinetics and potency o ...... ment therapy and contraception
@en
Pharmacokinetics and potency o ...... ment therapy and contraception
@nl
type
label
Pharmacokinetics and potency o ...... ment therapy and contraception
@ast
Pharmacokinetics and potency o ...... ment therapy and contraception
@en
Pharmacokinetics and potency o ...... ment therapy and contraception
@nl
prefLabel
Pharmacokinetics and potency o ...... ment therapy and contraception
@ast
Pharmacokinetics and potency o ...... ment therapy and contraception
@en
Pharmacokinetics and potency o ...... ment therapy and contraception
@nl
P3181
P356
P1476
Pharmacokinetics and potency o ...... ment therapy and contraception
@en
P2093
Frank Z Stanczyk
P2888
P304
P3181
P356
10.1023/A:1020072325818
P407
P577
2002-09-01T00:00:00Z
P6179
1005470409